Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
Public ClinicalTrials.gov record NCT01495793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system. The study was conducted in adolescent subjects (13 to \<18 years of age) with idiopathic Restless Legs Syndrome (RLS).
Study identification
- NCT ID
- NCT01495793
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2011 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Apr 4, 2018
2011 – 2014
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sp1004 006 | Little Rock | Arkansas | — | — |
| Sp1004 012 | Los Angeles | California | — | — |
| Sp1004 009 | Orange | California | — | — |
| Sp1004 005 | Washington D.C. | District of Columbia | — | — |
| Sp1004 014 | Spring Hill | Florida | — | — |
| Sp1004 013 | Indianapolis | Indiana | — | — |
| Sp1004 001 | Destrehan | Louisiana | — | — |
| Sp1004 015 | St Louis | Missouri | — | — |
| Sp1004 007 | West Seneca | New York | — | — |
| Sp1004 002 | Cincinnati | Ohio | — | — |
| Sp1004 016 | West Chester | Pennsylvania | — | — |
| Sp1004 003 | Austin | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01495793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2018 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01495793 live on ClinicalTrials.gov.